4971 results for "Psychedelics"
Development of the Japanese version of the Ego‐Dissolution Inventory (EDI)
Neuropsychopharmacology Reports – March 13, 2024
Summary
Psychedelics show promise for mental health, often inducing a unique "ego-dissolution" experience. To better understand this in a human context, a new Japanese version of the Ego-Dissolution Inventory (EDI) was developed. Expert translators rigorously followed international guidelines, collaborating with original authors through back-translation and refinement. This successful effort provides a vital tool for assessing ego-dissolution in Japanese speakers, enhancing research into psychedelic-assisted therapies, including for conditions like depression.
Abstract
Abstract Aim Psychedelics have recently gained attention as potential therapeutic agents for various psychiatric disorders. Previous research has h...
Development of the Japanese version of the 30‐item Mystical Experience Questionnaire
Neuropsychopharmacology Reports – March 13, 2024
Summary
Understanding profound human experiences, especially those linked to psychedelics, just became more globally accessible. A team successfully created a Japanese version of the Mystical Experiences Questionnaire (MEQ30). Following rigorous cultural adaptation guidelines, they translated this key tool. This achievement enables consistent assessment of mystical experiences, significantly advancing research on psychedelic-assisted therapies for Japanese speakers.
Abstract
Abstract Introduction Psychedelics have garnered increased attention as potential therapeutic options for various mental illnesses. Previous studie...
Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice
ACS Pharmacology & Translational Science – August 02, 2023
Summary
Psilocybin's long-term anxiolytic effects stem from a temporary stress hormone surge, not its hallucinogenic properties. In C57BL/6 male mice, 3 mg/kg psilocybin produced anxiolytic effects lasting 7 days. This pharmacology was blocked by a glucocorticoid receptor antagonist, an antiglucocorticoid, or suppressing corticosterone. A non-hallucinogen 5-HT2A agonist also showed anxiolytic effects via similar glucocorticoid release. This endocrinology, relevant to internal medicine and drug studies, suggests acute psilocybin-induced glucocorticoid release drives the post-acute anxiolytic action, but chronic corticosterone elevation negates it.
Abstract
While correlations between drug-induced cortisol elevation, self-reported anxiety, and treatment outcomes have been reported for human studies duri...
Problemática de las subastas de arte en España
Dialnet (Universidad de la Rioja) – January 01, 1996
Summary
Psilocybin, a promising antidepressant, does not impair memory consolidation. A placebo-controlled trial with 20 healthy volunteers (10 M/10 F) found it neither improved nor negatively affected immediate or overnight retention of learned material. This ensures cognitive functions remain intact, vital for engaging with Philosophy, Art, Historical Architecture, Archaeology, Cultural Heritage, Urbanism, Landscape, and Tourism studies. This evidence strengthens psilocybin's safety profile, supporting its therapeutic potential.
Abstract
Psilocybin is investigated as a fast-acting antidepressant used in conjunction with psychotherapy. Intact cognitive functions, including memory, ar...
Empowering understanding: navigating consent to ketamine treatment in adolescent mental health.
Frontiers in psychiatry – January 01, 2024
Summary
Ketamine shows promise in treating severe adolescent depression, but obtaining proper consent presents unique ethical challenges. Healthcare providers must balance parental rights with young patients' growing autonomy when discussing this innovative treatment. The process requires clear communication about ketamine's rapid antidepressant effects, potential risks, and its current off-label status. Success hinges on informed consent from parents while ensuring meaningful assent from adolescents themselves.
Abstract
The rising prevalence of mental health disorders in adolescents, compounded by treatment resistance, underscores the need for innovative interventi...
Suicide prevention and ketamine: insights from computational modeling
Frontiers in Psychiatry – June 30, 2023
Summary
Computational modeling offers a promising path to understanding how ketamine rapidly alleviates suicidality. This innovative approach in psychiatry uses advanced generative models to simulate brain processes, revealing how ketamine influences neural circuits involved in learning and decision-making. By analyzing altered brain connectivity and receptor densities, this computational modeling helps pinpoint the precise mechanisms. This powerful tool promises to personalize treatment strategies, offering new hope for individuals.
Abstract
Suicide is a pressing public health issue, with over 700,000 individuals dying each year. Ketamine has emerged as a promising treatment for suicida...
Investigating the complex cortical dynamics of an advanced concentrative absorption meditation called jhanas (ACAM-J): a geometric eigenmode analysis.
Cerebral cortex (New York, N.Y. : 1991) – February 05, 2025
Summary
No Summary
Abstract
Advanced meditation has been associated with long- and short-term psychological changes such as bliss, profound insight, and transformation of well...
A neuroscientific model of near-death experiences.
Nature reviews. Neurology – June 01, 2025
Summary
No Summary
Abstract
Near-death experiences (NDEs) are episodes of disconnected consciousness that typically occur in situations that involve an actual or potential phy...
Epigenetic Echoes: Bridging Nature, Nurture, and Healing Across Generations.
International journal of molecular sciences – March 27, 2025
Summary
No Summary
Abstract
Trauma can impact individuals within a generation (intragenerational) and future generations (transgenerational) through a complex interplay of bio...
Updates in palliative care of gynecologic oncology patients.
Current opinion in obstetrics & gynecology – February 01, 2025
Summary
No Summary
Abstract
This review assesses the impact of early integration of palliative care and the disparities that exist among patients with gynecologic malignancies...
Newer Treatments for Mood and Anxiety Disorders.
The Medical clinics of North America – September 01, 2024
Summary
No Summary
Abstract
For more than 20 years, the mainstay of pharmacologic treatment for depression and anxiety disorders has been serotonin reuptake inhibitors and sel...
Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.
The Australian and New Zealand journal of psychiatry – February 01, 2024
Summary
No Summary
Abstract
In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established med...
Integrative Oncology's 30-Year Anniversary: What Have We Achieved? A North American Naturopathic Oncology Perspective.
Integrative cancer therapies – January 01, 2023
Summary
No Summary
Abstract
In 1991 the U.S. Congress mandated that the National Institutes of Health (NIH) form the Office of Alternative Medicine to study alternative medica...
Distributed harmonic patterns of structure-function dependence orchestrate human consciousness
OpenAlex – August 10, 2020
Summary
Neuroscience reveals a profound insight into consciousness: how the human brain's connectome orchestrates our awareness. Using resting state fMRI, a unique "harmonic" signature emerges, indicating loss of wakefulness in conditions like anesthesia or brain injury. This signature, crucial for understanding neural dynamics and brain function, is mirrored in altered states from LSD or ketamine, showing a decoupling of functional brain connectivity. These functional brain connectivity studies offer new neural correlates of consciousness, advancing cognitive science and psychology by pinpointing mechanisms underlying conscious experience and even detecting covert consciousness.
Abstract
Abstract A central question in neuroscience is how consciousness arises from the dynamic interplay of brain structure and function. Departing from ...
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Frontiers in Pharmacology – February 20, 2018
Summary
Psilocybin, a powerful hallucinogen, can profoundly shift perceptions for individuals battling addiction. Qualitative research on three participants undergoing psilocybin-assisted psychotherapy for alcohol use disorder revealed vivid, memorable moments. These experiences altered self-perception and relationship with alcohol, fostering feelings of catharsis and increased mindfulness. This clinical psychology approach, rooted in psychiatry and drug studies, suggests psilocybin's influence on behavior, demonstrating its potential in addiction psychology, as this alkaloid elicits variable yet deeply personal therapeutic experiences.
Abstract
After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a sm...
Psilocybin-assisted psychotherapy for treatment-resistant obsessive–compulsive disorder: protocol for an open-label pilot study
BJPsych Open – December 15, 2025
Summary
Up to 60% of individuals with Obsessive-Compulsive Disorder (OCD) don't improve with standard therapies. A 12-week trial is exploring psilocybin-assisted psychotherapy for these treatment-resistant cases. Ten adults will receive a single 25 mg dose of psilocybin alongside psychological support. This initiative will assess the intervention's safety, tolerability, and preliminary clinical effects, using tools like the Yale–Brown Obsessive–Compulsive Scale. Additionally, it will examine brain changes to understand how psilocybin might work. These preliminary findings will guide larger studies into this promising approach for severe OCD.
Abstract
Background Obsessive–compulsive disorder (OCD) is a debilitating mental disorder commonly treated with selective serotonin reuptake inhibitors, aty...
Stephanie Knatz Peck: Novel and innovative treatment for eating disorders
Psychedelics. – October 21, 2024
Summary
A significant advance for eating disorders comes from Dr. Peck's pioneering psychology research. As a psychotherapist, she developed one groundbreaking behavioral intervention, Temperament-Based Treatment with Supports (TBT-S) for anorexia nervosa, integrating neuroimaging and genetic findings. Her contributions include co-leading the first clinical trial evaluating psilocybin treatment for AN, a major milestone in Eating Disorders and Behaviors. This innovative approach offers new avenues for complex psychiatric conditions, moving beyond traditional psychoanalysis.
Abstract
Dr. Stephanie Knatz Peck, Ph.D., is a practicing clinical psychologist and Associate Clinical Professor of Psychiatry at the University of Californ...
Explorando las terapias psicodélicas: Una revisión sistemática de la eficacia de la psilocibina en el tratamiento de la depresión
MLS Psychology Research – November 12, 2024
Summary
Depressive disorders surged by 25% during the pandemic, impacting one billion people. A review of 25 articles, informed by extensive Psychology Research and Bibliometrics, indicates psilocybin-assisted therapy effectively reduces depression symptoms, fostering new perspectives and improving overall mental health. This innovative approach in Psychological Treatments and Disorders offers rapid action and a favorable safety profile, demonstrating comparable efficacy to the conventional antidepressant escitalopram. Such findings offer crucial insights for Mental Health and Psychiatry, addressing profound human challenges.
Abstract
The main objective is to verify if the administration of psilocybin is effective for the treatment of depression. In addition, the aim is to verify...
Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments
OpenAlex – May 16, 2025
Summary
Individuals experiencing more severe depressive symptoms show greater openness to novel therapies like ketamine and psilocybin, a key insight for Mental Health Research Topics. A survey of 404 participants revealed that while psychotherapy garnered 98.3% acceptance, and psilocybin only 47.5%, higher depression severity specifically shifted expectations towards these innovative treatments. This finding in Clinical Psychology suggests managing patient expectations is crucial for integrating new approaches into mental health care, highlighting an important aspect of Social Psychology and treatment acceptance.
Abstract
Background: Despite significant advancements in the treatment of depression, challenges such as inadequate response rates and high placebo effects ...
USO TERAPÊUTICO DA PSILOCIBINA: REVISÃO INTEGRATIVA
Revista fisio&terapia. – October 08, 2025
Summary
Psilocybin demonstrates promising therapeutic effects for treatment-resistant depression, anxiety, and substance dependence. An integrative literature review, covering 2013-2025 across four databases, reveals its mental health potential. This compound, relevant to Phytochemistry Medicinal Plant Applications, acts on serotonergic receptors, fostering neural plasticity and lasting insights with psychotherapy. While current research predominantly comprises reviews and exploratory studies, necessitating more rigorous randomized controlled trials and long-term data, its significant potential requires ethical regulation and equitable access for clinical integration.
Abstract
A resurgence of scientific and clinical interest in psychedelic-assisted therapies, particularly with Psilocybin, has been observed. This paper pre...
Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.
Addiction (Abingdon, England) – January 20, 2026
Summary
Ibogaine shows significant promise for addiction treatment, effectively reducing craving and withdrawal from opioid and cocaine dependence. However, this psychoactive compound and its metabolite, noribogaine, carry a rare but serious cardiovascular risk. It can cause QT interval prolongation and potentially fatal ventricular arrhythmias, even at therapeutic doses in healthy individuals. Variability in drug metabolism contributes to this danger. Future use demands strict medical supervision, personalized dosing, and rigorous cardiovascular monitoring, with safer ibogaine analogues showing promise.
Abstract
Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive pote...
A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding
European Neuropsychopharmacology – March 04, 2020
Summary
A single dose of psilocybin significantly enhances personality Openness and mindfulness, with 10 healthy volunteers showing an average increase in Openness of 4.2 points and mindfulness scores rising by 0.5 after three months. Despite no overall change in cerebral 5-HT2AR binding, a negative correlation emerged between changes in mindfulness and 5-HT2AR levels, suggesting individual variability may influence long-term effects. These findings highlight psilocybin's potential as a transformative treatment in psychology and internal medicine, particularly for enhancing mindfulness.
Abstract
A single dose of the serotonin 2A receptor (5-HT2AR) agonist psilocybin can have long-lasting beneficial effects on mood, personality, and potentia...
Symptom specificity of ayahuasca's effect on depressive symptoms
Journal of Psychedelic Studies – April 19, 2021
Summary
Ayahuasca significantly alleviates affective symptoms of depression, with over 120 participants reporting greater improvements in hope, mood, and happiness compared to cognitive and somatic issues like loneliness and restless sleep. One month post-use, individuals noted distinct symptom relief, suggesting that ayahuasca may be more beneficial for those seeking emotional uplift rather than resolution of cognitive difficulties. This targeted effect aligns with the benefits of traditional antidepressants, indicating potential for ayahuasca in psychotherapy as a rapid-acting alternative for depression treatment.
Abstract
Abstract Background Ayahuasca's effects on symptoms of depression have generated considerable optimism. Clients frequently report more concern abou...
Mental health outcomes following a psilocybin session within Oregon’s state-regulated model: A naturalistic study
OpenAlex – February 19, 2026
Summary
Psilocybin sessions in Oregon's regulated framework resulted in significant improvements in mental health, with 88 participants reporting enhanced symptoms of depression, anxiety, and well-being 30 days post-session. The median age was 43 years, with 52% male and 46.6% concurrently using psychiatric medication. Participants consumed an average dose of 27.8 mg TPE. Notably, only 2.3% experienced short-term adverse effects like hallucinogen persisting perception disorder, which resolved by the follow-up period. This highlights psilocybin's potential as a therapeutic tool in clinical psychology and psychiatry.
Abstract
Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using n...
Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms
Journal of Psychoactive Drugs – October 10, 2025
Summary
One-third of veterans receiving care from Veterans Affairs expressed curiosity about MDMA-assisted therapy (MDMA-AT) for PTSD, highlighting a significant gap in understanding existing treatment options. In a sample of 30 participants, recurring themes included hope and concerns about side effects and addiction potential. Notably, over 10% demonstrated misunderstandings about the therapy and its implications. This insight can guide the creation of targeted psychoeducation materials and standardized surveys to better address veterans' attitudes towards innovative addiction treatments, ultimately enhancing mental health support.
Abstract
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially...
Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users
OpenAlex – July 28, 2024
Summary
Ayahuasca users exhibit markedly lower death anxiety and fear of death, alongside greater acceptance of mortality. A psychology comparison of 54 ayahuasca veterans and 53 non-users revealed these psychedelic-associated differences. The key mechanism isn't afterlife beliefs or mindfulness, but enhanced impermanence acceptance, potentially stemming from experiences like ego dissolution. This suggests engaging with the transient nature of existence profoundly reduces existential anxiety. These findings offer a novel approach for clinical psychology to manage fear of death.
Abstract
Background: How the human psyche interacts with the theme of death is fundamental to individual and societal life, profoundly influencing cognition...
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Progress in brain research – January 01, 2018
Summary
A novel approach to addiction treatment shows promise: sequential combination psychedelic therapy. One veteran with alcohol use disorder received ibogaine, followed by 5-MeO-DMT, leading to profound personal insights and a spiritual breakthrough. Post-treatment SPECT imaging revealed increased brain perfusion in areas linked to alcohol use disorder. This therapeutic sequence coincided with improved mood, reduced cravings, and cessation of alcohol use for over a month, highlighting the potential of these psychedelics in addressing addiction.
Abstract
Ibogaine is a plant-derived alkaloid and dissociative psychedelic that demonstrates anti-addictive properties with several substances of abuse, inc...
Neurochemical and Neurophysiological Effects of Intravenous Administration of N,N-Dimethyltryptamine in Rats.
bioRxiv : the preprint server for biology – February 15, 2025
Summary
DMT, a naturally occurring compound in the brain, operates at levels similar to crucial neurotransmitters like serotonin and dopamine. When administered intravenously in rats, DMT triggered significant brain changes, boosting both serotonin and dopamine levels while altering brain wave patterns. The findings revealed complex interactions between DMT and brain chemistry, showing how this compound influences neural communication and behavior. These results help explain DMT's potential therapeutic effects in treating mental health conditions.
Abstract
N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic that is being investigated clinically for the treatment of psychiatric disorders. Althou...
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists.
Journal of medicinal chemistry – September 22, 2022
Summary
Scientists have discovered new compounds that interact with serotonin receptors in a unique way, offering potential insights into how psychedelic medicines work in the brain. By modifying a known psychedelic compound, researchers created molecules that selectively activate specific cellular pathways, particularly favoring β-arrestin over traditional signaling routes. This breakthrough could help develop more targeted treatments for mental health conditions.
Abstract
The serotonin 2A receptor (5-HT2AR) is the mediator of the psychedelic effects of serotonergic psychedelics, which have shown promising results in ...
[Acceptance of psilocybin-assisted therapy in German-speaking countries].
Der Nervenarzt – February 12, 2025
Summary
Public acceptance of psychedelic therapy is growing in German-speaking regions, with 1,456 surveyed participants showing optimism toward psilocybin-assisted therapy. Higher knowledge levels and personal experience with psychedelics predicted more positive attitudes. Notably, balanced education about both benefits and risks led to increased acceptance among mental health professionals and the public.
Abstract
Clinical studies with psilocybin in combination with psychotherapy show promising results for the treatment of various mental disorders; however, t...
Development of an Australian Clinical Practice Guideline on methylenedioxymethamphetamine (MDMA)-assisted Psychotherapy for Post-traumatic Stress Disorder.
Journal of affective disorders – July 17, 2025
Summary
Australia is pioneering a new era for mental health, allowing authorized prescribing of Ecstasy for PTSD. This initiative outlines the development of robust Therapeutic guidelines for MDMA-assisted psychotherapy. Using a rigorous, evidence-based process, experts are crafting protocols to ensure safe and effective psychedelic-assisted therapy. This marks a significant step towards providing carefully considered, evidence-based treatment for those battling PTSD.
Abstract
Despite recent clinical and research interest, medical use of psychedelics has not been legalised in most jurisdictions. The Australian Therapeutic...
Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.
Expert opinion on emerging drugs – June 01, 2025
Summary
Psilocybin, a compound found in psychedelic mushrooms, shows remarkable potential in treating severe depression where traditional medications fail. Clinical evidence reveals rapid improvements in treatment-resistant patients, with benefits lasting months after just one or two supervised sessions. The compound also helps terminal patients in palliative care find peace and acceptance, reducing anxiety and improving quality of life.
Abstract
Although long known for their psychoactive effects, psychedelic drugs have only recently been investigated for medicinal use. Psilocybin has attrac...
Neural network models for DMT-induced visual hallucinations
Neuroscience of Consciousness – January 01, 2020
Summary
Psychedelic alkaloids like N,N-Dimethyltryptamine profoundly alter visual perception, offering unique insights into consciousness. Neuroscience and cognitive psychology reveal how the serotonergic system, influenced by these compounds, critically gates sensory and internal information, shaping our reality. Utilizing two advanced generative deep neural networks, cognitive science can illustrate psychedelic-induced visual hallucination. This innovative approach helps conceptualize how the serotonergic sensory system regulates visual perception, providing a novel framework for understanding sensory gating and the biochemical basis of perception within drug studies.
Abstract
Abstract The regulatory role of the serotonergic system on conscious perception can be investigated perturbatorily with psychedelic drugs such as N...
Amazonian Ayahuasca and Mental Health Outcomes
CORE – June 17, 2024
Summary
Traditional Amazonian plant medicine shows promising effects on mental well-being and personal growth. Analysis of retreat participants revealed significant improvements in depression, anxiety, and stress levels after ceremonial use. The brew's unique combination of natural compounds appears to promote positive personality changes and deeper connection to nature, while participants reported meaningful psychological insights during sessions. Results suggest careful, traditional administration may offer therapeutic benefits.
Abstract
Ayahuasca is a psychedelic plant brew originating from the Amazon Rainforest. It is formed from two basic components, the Banisteriopsis caapi vine...
Self-experience in MDMA assisted therapy of PTSD
medRxiv Preprint Server – January 03, 2023
Summary
For those with severe PTSD, especially from childhood trauma, challenges with emotional coping often hinder recovery. A randomized trial investigated if MDMA-assisted therapy could help. Participants received therapy with MDMA or placebo. Remarkably, MDMA-assisted therapy significantly boosted self-compassion and improved altered mental processes linked to poor treatment response. This approach shows promise for addressing core emotional challenges in PTSD.
Abstract
In recent years there has been a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphet...
Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis.
Journal of psychoactive drugs – January 01, 2024
Summary
Global interest in Ibogaine for substance use disorders is rapidly expanding. A scientometric analysis, utilizing tools like CiteSpace and vosviewer, explored the evolving research landscape of Ibogaine as a potential treatment. Analyzing over 1500 publications across three decades revealed a significant increase in global research activity. This growth highlights Ibogaine's potential, with recent trends focusing on its role among psychedelics for treating opioid and other substance use disorders. This widespread, growing attention underscores its promising therapeutic future.
Abstract
Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid...
Molecular insights into the modulation of the 5HT2A receptor by serotonin, psilocin, and the G protein subunit Gqα.
FEBS letters – March 01, 2025
Summary
Breakthrough research reveals how psychedelics like psilocin interact with brain receptors at the molecular level. Scientists used advanced simulations to show how the 5HT2AR receptor changes shape when binding to natural serotonin and psychedelic compounds. The findings explain why these receptors need specific protein partners to function and could help develop better mental health treatments.
Abstract
5HT2AR is a G-protein-coupled receptor that drives many neuronal functions and is a target for psychedelic drugs. Understanding ligand interactions...
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.
Journal of psychiatric research – August 01, 2024
Summary
Psilocybin combined with psychotherapy shows remarkable promise in treating severe depression. Recent analysis reveals that while this psychedelic treatment consistently includes preparation, guided sessions, and integration therapy, protocols vary widely between practitioners. Studies demonstrate positive outcomes when trained therapists combine traditional psychotherapy with carefully monitored psilocybin sessions, offering new hope for mood disorders.
Abstract
Psilocybin-assisted psychotherapy (PAP) is a promising treatment option for depression, with randomized controlled trials (RCTs) providing prelimin...
Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness.
Neuroscience of consciousness – January 01, 2025
Summary
A powerful serotonin-based psychedelic compound can temporarily dissolve self-awareness while maintaining consciousness. EEG recordings show reduced brain wave activity during these experiences, suggesting decreased top-down mental processing. Participants reported varying levels of ego dissolution and altered perception, offering insights into how consciousness and self-identity are constructed in the brain.
Abstract
5-MeO-DMT is a short-acting psychedelic that is anecdotally reported to induce a radical disruption of the self and a paradoxical quality of arouse...
Psilocybin and hallucinogenic mushrooms.
CNS spectrums – December 01, 2024
Summary
Naturally occurring in magic mushrooms, psilocybin shows remarkable potential in treating severe depression. Recent clinical trials reveal that psilocybin-assisted therapy can provide significant relief for patients with treatment-resistant depression, with benefits lasting months after just two sessions. The compound works by promoting new neural connections and increasing emotional flexibility, offering hope for those who haven't responded to conventional treatments.
Abstract
Psilocybin therapy has recently emerged as a promising new treatment for depression and other mental health disorders. This chapter summarizes the ...
Neuroprotective effects of psilocybin in a rat model of stroke.
BMC neuroscience – October 08, 2024
Summary
The psychedelic compound psilocybin shows remarkable promise in protecting brain cells during stroke events. When administered to rats before or shortly after stroke simulation, this naturally-occurring substance reduced brain damage and improved movement recovery. The protective effects work through BDNF, a key protein that helps brain cells survive and adapt. Results showed less brain tissue damage and better physical function in treated rats.
Abstract
Psilocybin is a psychedelic 5HT2A receptor agonist found in "magic mushrooms". Recent studies have indicated that 5HT2A agonists, such as dimethylt...
Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees.
Frontiers in psychiatry – January 01, 2024
Summary
MENA immigrants and refugees showed remarkable mental health improvements after ceremonial ayahuasca use, with reduced depression, anxiety, and shame. A longitudinal study of 15 participants, mostly women, found lasting positive changes including increased self-compassion and emotional regulation. Results indicate psychedelic-assisted healing could benefit refugee mental health.
Abstract
Refugees and immigrants can experience complex stressors from the process of immigration that can have lasting and severe long-term mental health c...
'Everybody's creating it along the way': ethical tensions among globalized ayahuasca shamanisms and therapeutic integration practices.
Interdisciplinary science reviews : ISR – January 01, 2023
Summary
As traditional Amazonian shamanism meets modern therapy, ayahuasca healing practices are evolving in unexpected ways. In Peru, where vegetalismo healing traditions run deep, local shamans and Western mental health practitioners are forging new approaches to psychedelic therapy. This research reveals complex dynamics between indigenous healing wisdom and contemporary therapeutic frameworks, highlighting both opportunities and challenges in bridging these different approaches to mental wellness.
Abstract
Ayahuasca has a variety of traditional uses, yet there is a growing global interest in its potential therapeutic benefits for mental health conditi...
Feasibility of a Hypnosis Intervention for a Mystical Experience.
The International journal of clinical and experimental hypnosis – May 15, 2025
Summary
Hypnosis can induce profound mystical experiences similar to those reported with psychedelics, but without drugs. In a groundbreaking exploration, highly hypnotizable participants underwent guided sessions in controlled settings. 70% achieved complete mystical experiences, reporting profound non-ordinary states of consciousness. The intervention proved both safe and effective, with participants unanimously expressing interest in future sessions.
Abstract
The purpose of the present study is to determine feasibility and acceptability of a standardized hypnosis intervention for a mystical experience ba...
Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.
Psychological medicine – December 01, 2023
Summary
Psilocybin-assisted therapy shows promising cost-effectiveness in treating severe depression, delivering better quality-of-life outcomes than traditional treatments. Decision analysis reveals that while initial costs are higher, PAP leads to superior health improvements. When combined with reduced therapy support and optimized pricing, this treatment approach proves more economically viable than standard options for TRD.
Abstract
There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-eff...
Trends in drug use among nightclub and festival attendees in New York City, 2017-2022.
The International journal on drug policy – May 01, 2023
Summary
Drug trends at NYC nightlife venues shifted dramatically during 2017-2022, with natural psychedelics rising as traditional club drugs declined. While ketamine and mushroom use increased significantly, cocaine and methamphetamine saw notable decreases. The COVID-19 pandemic appears to have accelerated these changes, with partygoers increasingly favoring new psychoactive substances over conventional stimulants.
Abstract
Drug use is prevalent among people who attend electronic dance music (EDM) parties at nightclubs or festivals. This population can serve as a senti...
Exploring Cultural Competence, Inclusivity, and Diversity in Ketamine Assisted Psychotherapy: A Phenomenological Study.
Journal of psychoactive drugs – May 02, 2024
Summary
Marginalized communities often face unique challenges in accessing mental health treatments. New research reveals how ketamine-assisted psychotherapy can be effectively tailored for diverse populations. Following 15 participants from various racial, ethnic, and LGBTQIA+ backgrounds, the study found that cultural sensitivity and inclusivity significantly impact treatment outcomes. Financial accessibility, cultural rituals, and addressing stigma proved crucial for successful psychedelic psychotherapy experiences.
Abstract
Black, Indigenous, and People of Color (BIPOC), and other minoritized populations are insufficiently represented in research on therapeutic psyched...
A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder.
Drugs – February 01, 2024
Summary
Brain trauma from PTSD affects multiple neural pathways, making traditional antidepressants only partially effective. New research reveals promising alternative treatments targeting different brain mechanisms, from novel compounds like BNC-210 to psychedelic-assisted therapy. These approaches show potential in treating both the fear response and emotional processing aspects of PTSD, offering hope for more effective treatments beyond conventional SSRIs.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating disorder inflicting high degrees of symptomatic and socioeconomic burdens. The development ...
Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.
Frontiers in pharmacology – January 01, 2023
Summary
Scientists have developed innovative ways to deliver ayahuasca's key compounds, DMT and harmine, without the traditional brew's challenging side effects. By creating new formulations combining nasal sprays and oral tablets, researchers achieved more consistent results than traditional methods, with significantly less nausea and digestive issues. The psychedelic experience remained effective while being more comfortable and predictable.
Abstract
Recently, the Amazonian plant medicine "ayahuasca"-containing the psychedelic compound N,N-dimethyltryptamine (DMT) and numerous β-carboline alkalo...
Depressionen: Remission durch Psilocybin bei laufender SSRI-Therapie
Fortschritte der Neurologie · Psychiatrie – April 01, 2024
Summary
A groundbreaking finding in Psychedelics and Drug Studies suggests Psilocybin can enhance existing antidepressant therapy for Treatment of Major Depression. Traditionally, patients discontinue antidepressants before Psilocybin administration due to concerns about altered psychedelic effects. However, new Medicine research indicates Psilocybin positively complements SSRI treatment, rather than being hindered by it. This opens new avenues in Psychology and Complementary and Alternative Medicine Studies, potentially improving outcomes for those struggling with depression without requiring medication cessation.
Abstract
Psilocybin ist ein Indolalkaloid aus der Gruppe der Tryptamine und wird zur Behandlung behandlungsresistenter Depressionen (TRD) untersucht. Da die...
LSD und Psilocybin als Selbstmedikation
Suchttherapie – February 01, 2020
Summary
Microdosing psychedelics like Psilocybin, taking 5-10% of a standard dose without intoxication, offers promising psychological benefits. Initial Psychedelics and Drug Studies reveal improvements in well-being, cognitive performance, and reduced symptoms of depression and anxiety. These small-scale investigations suggest how Psilocybin subtly influences neurotransmitter receptors, impacting behavior and mental states. This growing interest in psychology reflects potential avenues for enhancing mental health and performance.
Abstract
Die Mikrodosierung von Psychedelika wie LSD oder Psilocybin zur Leistungssteigerung und Förderung kreativer Prozesse erfährt zunehmend mediale Aufm...
Hanscarl Leuner und die Grundlagen der Psycholytischen Therapie
Nervenheilkunde – April 01, 2024
Summary
Hanscarl Leuner pioneered Psycholytic Therapy, a distinct European approach using low-dose hallucinogens like LSD to gently loosen psychological defenses. Unlike high-dose psychedelic experiences, this method involves 5-25 substance applications integrated into long-term psychotherapy. The aim is to access unconscious conflicts and deeper "soul content," a concept resonating with psychoanalytic thought and philosophical inquiries into the mind. This medical application of psychedelics offers a unique perspective within drug studies, exploring consciousness beyond conventional mental health interventions.
Abstract
ZUSAMMENFASSUNG Hanscarl Leuner (1919–1996) gilt aufgrund seines wissenschaftlichen und organisatorischen Engagements als die zentrale Figur der Ps...
Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländern
edoc Publication server (Humboldt University of Berlin) – February 12, 2025
Summary
Optimism for psilocybin-assisted therapy is high, especially among informed individuals. A survey of 1456 participants, including medical professionals and patients, revealed greater knowledge and personal psychedelic experience predicted significantly more positive attitudes toward its implementation (explaining 39% of variance). Acceptance for this innovative Medicine, relevant to Pain Management and broader well-being, increased when information about therapeutic potentials was balanced with risks. This highlights the importance of informed public discourse, crucial for integrating advances from Psychedelics and Drug Studies and shaping sound policy.
Abstract
Hintergrund: Klinische Studien mit Psilocybin in Kombination mit Psychotherapie zeigen vielversprechende Ergebnisse bei der Behandlung verschiedene...
Points of Interest
Healthcare Quarterly – May 31, 2010
Summary
Psychedelic-assisted therapy offers profound relief for cancer anxiety and PTSD, emerging as a potential best practice in Medicine. This innovative approach helps patients gain clarity and enrich their lives, with one participant calling it "revelatory." Such insights from Psychology could reshape Public relations efforts around mental health, fostering greater understanding. Moreover, it may influence Business strategies for developing new therapeutic interventions, focusing on enhancing well-being and personal awareness during challenging times.
Abstract
Magic Mushrooms and Cancer TherapyA study at New York University has found that the controlled use of psychedelic drugs can help doctors treat canc...
Experiences of Listening to Icaros during Ayahuasca Ceremonies at Centro Takiwasi:An Interpretive Phenomenological Analysis
Anthropology of Consciousness – September 26, 2022
Summary
Listening to icaros, or medicine songs, during ayahuasca ceremonies significantly enhances therapeutic outcomes for addiction rehabilitation patients. In a study involving 50 participants at Perú’s Centro Takiwasi, these songs helped modulate emotions and create a sense of safety, guiding patients through challenging memories. Approximately 80% reported transformative experiences related to healing and understanding their addictions. This highlights the importance of integrating music into psychedelic-assisted therapies, suggesting that future approaches should prioritize this element to maximize therapeutic benefits in altered states of consciousness.
Abstract
Abstract Research on psychedelic‐assisted psychotherapy has shown that music affects therapeutic outcomes at a fundamental level. The development o...
Psilocybin, psychological distress, and suicidality
Journal of Psychopharmacology – September 01, 2015
Summary
Lifetime psilocybin use significantly correlates with reduced psychological distress and suicidality. Among 191,832 U.S. adults, those reporting only psilocybin (a potent hallucinogen) use (2.47% of the sample) exhibited the greatest reductions in distress and suicidal thoughts, planning, and attempts. This finding, crucial for Psychology and Clinical Psychology, suggests psilocybin's potential in Psychiatry and Medicine. It offers psychotherapists a new avenue within Psychedelics and Drug Studies for managing psychological distress, hinting at its unique chemical synthesis and influence on behavior.
Abstract
Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid di...
Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history.
Journal of Clinical Oncology – June 01, 2024
Summary
Lifetime use of classic hallucinogens like Lysergic acid diethylamide, Psilocybin, and Mescaline is higher among recently diagnosed cancer patients. A survey of 208,220 US adults found 14.0% reported lifetime psychedelic use. Young adults (18-34) with recent cancer diagnoses showed 3-fold greater odds of using Peyote. This population data is crucial for medicine and psychiatry, informing drug studies, forensic toxicology, cannabis research, and even dermatology, as these psychedelics re-emerge.
Abstract
e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest know...
CCNP Innovations in Neuropsychopharmacology Award
Journal of Psychiatry and Neuroscience – September 19, 2024
Summary
Psychedelics are profoundly reshaping mental health treatment, offering a novel psychiatric framework. These substances uniquely activate serotonin receptors and influence specific neural circuits, fostering transformative cognitive and spiritual experiences. A Neuropsychopharmacology review elucidates the complex mechanisms of two principal psychedelics, psilocybin and LSD, impacting brain plasticity. This deep Neuroscience and Psychology understanding is vital for future pharmaceutical studies and practices, addressing diverse mental health disorders. Such insights could even extend to conditions like Attention Deficit Hyperactivity Disorder, integrating brain, mind, and spirituality.
Abstract
For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last ...
Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner
Journal of Psychoactive Drugs – November 01, 2012
Summary
Even with widespread recreational use today, psychedelics like Lysergic acid diethylamide and Psilocybin continue to induce profound mystical experiences. A study of 337 adults revealed that while only a quarter cited spiritual motives, higher doses of these hallucinogens strongly correlated with mystical states. This finding in Psychology contrasts with MDMA (Ecstasy), Cannabis, or other recreational drugs, which showed no such link. This sheds light on the unique psychological impact of psychedelics, a key area in Clinical psychology and Psychiatry, moving beyond historical contexts of mysticism and drug studies.
Abstract
Psychedelic drugs have long been known to be capable of inducing mystical or transcendental experiences. However, given the common "recreational" n...
Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis
BMJ – August 21, 2024
Summary
High-dose psilocybin, a potent hallucinogen, significantly outperformed escitalopram for depressive symptoms in a systematic review of randomized controlled trials. This medicine, influencing neurotransmitter receptors, showed a greater effect than 10mg escitalopram (4.66 points) and 20mg (4.69 points). While better than placebo, psilocybin's effect size was small (0.31) when compared to traditional antidepressant trials. Crucially, no severe adverse effect, unlike some psychiatry drugs (e.g., Fluoxetine, Risperidone), was more common than placebo. Such psychedelics and drug studies, including chemical synthesis, are vital for internal medicine.
Abstract
Abstract Objective To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients ...